Will Promis Neurosciences Inc (OTCMKTS:ARFXF) Finally Overcome Alzheimer’s?

The high volatility of Promis Neurosciences Inc (OTCMKTS:ARFXF) has been a cause of concern for investors over the last year. However, the price recently jumped in value from $0.18 to $0.38 leaving early investors with no less than 100% returns. In our article today, we give insight as to the likely cause of the jump and our outlook on the firm going forward.Here is the stock’s price movement in the last year: ARFXF Daily ChartCompany ProfileProMIS Neurosciences is a development stage biotechnology firm which engages in discovering and developing drugs for treating neural afflictions such as Alzheimer's disease and amyotrophic lateral sclerosis. The firm applies its thermodynamic, calculated discovery platform and Collective Coordinates to forecast possible targets known as Disease Specific Epitopes on the surface of roughened proteins. Using this novel strategy, the firm develops new company is developing new drugs and solutions for the earlier mentioned diseases. It is headquartered in Toronto, Ontario, and has a branch in Cambridge, Massachusetts.In January 2018, the firm reported that PMN310, its main product for treatment of Alzheimer's, revealed an absence of binding to amyloid beta (Aβ) plaque close to the blood vessels in brain samples of Alzheimer’s patients during a clinical research which was focused on the direct comparison of PMN310 to other antibodies directed to Aβ. The joining of these antibodies to such Aβ deposits in the brain, within certain blood vessels, shows proof of the presence of Amyloid-related imaging abnormalities; which include swelling of the brain and microhemorrhages in treated AD patients.Elliot Goldstein, company President, and CEO explained that PMN310 was created to mainly work on the lethal, Aβ oligomers, which commonly known as the primary Alzheimer’s disease. By not working on just the Aβ plaque, primarily those located close to the brain, it is likely that the drug may not be linked with the brain swelling which is often associated with aducanumab. The ratification of a much safer profile in clinical tests would endorse the administering of increased amounts of the drug to Alzheimer patients, improving the ability of PMN310 to work.The binding profile of PMN310 in human AD brain tissue, as well as in brain samples from a mouse AD model, was directly compared to that of other Aβ-directed antibodies in a preclinical study using the technique of immunohistochemistry (IHC). Results of a search revealed the joining of aducanumab and bapineuzumab to Aβ plaque all around the brain tissue, as well as the blood vessels. On the other hand, joining of PMN310 to the Aβ plaque was not detected in anywhere with the Alzheimer brain tissues.Previous clinical results have proven that treatment using antibodies that work on the Aβ plaque, such as aducanumab (Biogen) and bapineuzumab (Johnson & Johnson) are connected with brain swelling and bleedings in a significant number of people living with Alzheimer’s. Aducanumab seems to work on both the Aβ plaque and Aβ oligomers, which experts often regard as the primary target. It has also been shown previous research results that PMN310 has an additional benefit of mainly working on the Aβ oligomers, without joining with the plaque, which allows for the administering larger portion of the PMN drug rather than aducanumb.Earlier in December, the company announced that its equity stock had been cleared for trading on the OTCQB Venture Market in the USA using the ticker “ARFXF." OTCQB is a United States trading exchange which is run by the OTC Markets Group in New York.The firm’s CEO explained that management was pleased to announce its novel trading affiliation with OTCQB. As part of its continuing plan to introduce the company to a global consumer base, the milestone would be used to provide greater awareness, improved admission to the U.S. trading market, and more ease in trading its equity stockThe OTCQB is mainly for new companies whether globally or within the U.S. To any firm listed on the exchange, it must have updated financial reports, have a bid price above $0.01 and be willing to undergo a yearly verification process.Financial ResultsThe firm recorded a net loss which is somewhat common for startup companies, especially when considering that research and development contribute the largest part of the firm’s expenses. The firm gas no interest or one-off expenses on its books.The firm was unable to retain its high liquidity ratio due to an increase in its payables. However, the firm has very little short-term debt which alleviates any fears of default of its loans. However, the drop in its assets might cause some concern when compared with the rise of total liabilities by over 50%.ConclusionThe level of progress the company has recorded in combating neurogenerative diseases may just lead to a breakthrough soon enough.We will be updating our subscribers as soon as we know more. For the latest updates on ARFXF, sign up below!Disclosure: We have no position in ARFXF and have not been compensated for this article.